Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LstCAR019
- Development stage
- Unknown
- Lead developer
- Chongqing Precision Biotech Co., Ltd
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
LstCAR019 is an anti-CD19 Universal CAR-T cell therapy being developed for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). This therapy involves genetically modifying T cells to target CD19, a protein expressed on the surface of B cells, including cancerous B cells. The therapy is administered intravenously following a 3-5 day lymphodepletion therapy regimen, primarily for patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia.
- Other names
- Anti-CD19 Universal CAR-T CellsAnti-CD-19 Universal CAR-T CellsAnti-CD 19 Universal CAR-T Cells
02
Targets
Beyond the preview
Go deeper on LstCAR019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LstCAR019.